ArticleScientific reports2023
The underestimated role of myopia in uncorrectable visual impairment in the United States.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Low-concentration atropine for management of myopia progression: does iris colour matter?Eye (London, England) · 2026Pooled it
- Dose Dependent Effects of Atropine on Static and Dynamic Pupil and Accommodation Metrics in Young Adults.Investigative ophthalmology & visual science · 2025Trial
- Axial Length to Corneal Curvature Ratio is Insufficient for Detecting Pseudomyopia in Children: A Multi-Cohort Study.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Article
- Evaluating the Effect on Emmetropization of the Timing and Spectrum of Breaks From a Myopiagenic Environment.Investigative ophthalmology & visual science · 2026Article
- Short-term effects of atropine on the retina and choroid in young adults.Eye and vision (London, England) · 2026Article
- Myopia Prescription Based on Smartphone App: A Feasibility Study in Africa.Translational vision science & technology · 2026Article
- Visual Neural Dynamics of Adolescents with Myopia During Face Inversion: An ERP and Oscillatory Study.Brain sciences · 2025Article
- Driving Performance Under Peripheral Defocus Induced by Ophthalmic Lenses for Myopia Control.Translational vision science & technology · 2025Article
- Current and emerging strategies for myopia control: a narrative review of optical, pharmacological, behavioural, and adjunctive therapies.Eye (London, England) · 2025Review
- IMI-Interventions for Controlling Myopia Onset and Progression 2025.Investigative ophthalmology & visual science · 2025Review
- Long-term surgical outcome of high myopic full-thickness macular hole without retinoschisis.BMC ophthalmology · 2025Article
- Childhood Myopia Part II: Treatment Mechanisms, Emerging Options, and Considerations.Investigative ophthalmology & visual science · 2025Review
- How Have Animal Models Increased our Understanding of Human Myopia?Investigative ophthalmology & visual science · 2025Review
- Myopia in Houston optometry graduates from 2013 to 2023.Optometry and vision science : official publication of the American Academy of Optometry · 2025Article
- Prediction of Myopia Among Undergraduate Students Using Ensemble Machine Learning Techniques.Health science reports · 2025Article
- Clinical advantages of multifocal soft contact lenses in myopia control for adolescents.American journal of translational research · 2025Article
- Trends in myopia prevalence and projected visual impairment in Western Europe: a pooled analysis of Dutch population-based cohorts (1900-2000).BMJ public health · 2025Article
- Biomarkers: Promising Tools Towards the Diagnosis, Prognosis, and Treatment of Myopia.Journal of clinical medicine · 2024Review
- Adult Myopia Progression.Investigative ophthalmology & visual science · 2024Article
- Optic Nerve Head Morphology and Macula Ganglion Cell Inner Plexiform Layer Thickness in Axially Anisometropic Rhesus Monkeys.Investigative ophthalmology & visual science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We estimate the US prevalence of uncorrectable visual impairment in 2050 accounting for the changing distribution of both age and myopia. Age projections of the US population (from an estimated total of 379 million in 2050), were taken from the US census website. The distribution of myopia, by severity, was calculated from literature-derived prevalence estimates of 58.4% (≤ - 0.50 D, 2050 projection) and 33.1% (≤ - 1.00 D, 1999-2004 estimate) to provide predicted and conservative estimates, respectively. Uncorrectable visual impairment as a function of age and refractive error was modelled by multiple linear regression. Finally, the likely number of individuals in the US with visual impairment in 2050 was calculated. For a projected myopia prevalence of 58.4%, 222 million are projected to be myopic and 48 million will have high myopia (- 5 D or worse). The projected total number with uncorrectable visual impairment is 11.4 million of which 4.9 million cases (43%) of visual impairment will be directly attributed to increased risk of eye disease associated with myopia. For a projected myopia prevalence of 33.1%, 8.9 million are projected to have uncorrectable visual impairment of which 2.4 million cases (27%) will be directly attributed to myopia. It is predicted that between 27 and 43% of uncorrectable visual impairment in the US population in 2050 will be directly attributable to myopia. Failure to account for the increasing prevalence of myopia among the aging population leads to a substantial underestimate of the prevalence of visual impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.